— Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — ...
Changes are expected to reduce future study costs, accelerate objective readouts, and extend operating runway under current plans SEATTLE, Oct. 6, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc.
Hosted on MSN
Atossa amends (Z)-endoxifen trial for breast cancer
Atossa Therapeutics has amended its Phase II EVANGELINE study of (Z)-endoxifen for premenopausal women with breast cancer to support New Drug Application (NDA) activities. This trial is intended for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results